Literature DB >> 28288264

Enhancing Transparency at the US Food and Drug Administration: Moving Beyond the 21st Century Cures Act.

Joshua M Sharfstein1, Michael Stebbins2.   

Abstract

Mesh：

Year:  2017        PMID： 28288264     DOI： 10.1001/jama.2017.2481

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Real-World Evidence: Promise and Peril For Medical Product Evaluation.

Authors:  Sanket S Dhruva; Joseph S Ross; Nihar R Desai
Journal:  P T       Date:  2018-08

2.  Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Authors:  Joshua D Wallach; Alexander C Egilman; Sanket S Dhruva; Margaret E McCarthy; Jennifer E Miller; Steven Woloshin; Lisa M Schwartz; Joseph S Ross
Journal:  BMJ       Date:  2018-05-24

3.  Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Authors:  Joshua D Wallach; Anita T Luxkaranayagam; Sanket S Dhruva; Jennifer E Miller; Joseph S Ross
Journal:  BMC Med       Date:  2019-06-17       Impact factor: 8.775

4.  Assessment of Public Opinion on Transparency at the US Food and Drug Administration.

Authors:  Tej D Azad; Caroline F Plott; Andrea C Gielen; Joshua M Sharfstein
Journal:  JAMA Netw Open       Date:  2022-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.